Medical and Health Science Journal

  Previous Article | Back to Volume | Next Article
  Abstract | References | Citation | Download | Preview | Statistics
Volume 8
Issue 4
Online publication date 2011-07-29
Title Effectiveness of I and II line chemo-targeted therapy according to the scheme Oxaliplatin Capecitabine Bevacizumab (XELOX BVZ) in patients with metastatic colorectal cancer (mCRC)
Author Kaldigul Smagulova, Nino Chichua, Zhetkergen Arzykulov, Suriya Yessentayeva, Ramil Abdrakhmanov, Assel Tumanova, Sholpan Mukanova, F. Мoldasheva
Abstract
The research involved 38 mCRC patients, aged 23-73 (medium age -55 years). Patients with mCRC were randomized into two groups. This mode of chemo-targeted therapy was conducted in the first group (20 patents) in a second line, since these patients previously were treated by the chemotherapy schemes FOLFIRI or FOLFOX.  Patients were treated in the mode: Capecitabine in 2000mg/m2 2 times a day from the 1st to the 14th day, 2-hour infusion of capsular Oxaliplatin 130mg/m2, day 1, Bevacizumab 5mg/kg 1 time per 14 days.
The overall objective effect was obtained in 15 patients (39.5±7.9) %: in group 1 - in 7 patients (35.0 10.6%), in the 2group - 8 cases (44.4±11.7%), of which complete regression - in 1 (5%) and 2 (11.1%) cases, respectively. In 30% of cases the partial response and a greater number of stabilization (50% and 44.5% respectively) were reported. Progression of the process was observed at 15% in a group 1 and 11.1% of cases in group 2. Terms of remission were group 1 - 8.2 months, group 2 - 12.1 months.
Thus, XELOX BEV shows the sufficient efficacy in patients with mCRC, both in I and II lines of chemotherapy, with an acceptable toxicity profile.

Citation
References
Arzykulov, Zh., Seitkazina, G., Igisinov, S. et al., 2010. Indicators of oncology services in the Republic of Kazakhstan for 2009, Almaty

Goldberg, R., Sargent, D., Morton, R. et al., 2004. “A randomized controlled trial of fluorouracill plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer’. J. Clin Oncol, pp.23-30 

Hurwitz, H., Fehrenbacher, L., Hainsworth, J. et al., 2004. “Bevacizumab in combination with 5-fluorouracil and leucovorin: A promising regime for first-line metastatic colorectal cancer,” Gastrointestinal Cancers Symposium, San Francisco, CA, p.182 (abctr 286)

Kabbinavar, F., Schulz, J., McCleod, M., et al., 2005. “Addition of bevacizumab to bolus 5-FU/leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial”. J Clin Oncol 23:10.1200/JCO. 2005.05.112

Saltz, L., Cox, J., Blanke, C., et al., 2000. “Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer:  Irinotecan Study Group”. N Engl J Med 343, pp.905-914
Schalhorn, A., Ludwig, F., et al., 2005. “Phase III trial of irinotecan plus oxaliplatin (IROX) versus irinotecan plus 5-FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): The FIRE-Trial”. Proc ASCO. 24, abstr. 3516

Keywords Colorectal cancer, liver metastases, chemo-targeted treatment, vascular endothelial growth factor (VEGF)
Pages 6-8
Download Full PDF Download
  Previous Article | Back to Volume | Next Article
Share
Search in articles
Statistics
Journal Published articles
MHSJ 940
Journal Hits
MHSJ 2615941
Journal Downloads
MHSJ 17529
Total users online -